Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Could octreotide become a first‑line systemic option in VWD patients with angiodysplasia‑related GI bleeding?
Great talk by Sophie Susen at the EHA meeting in Florence on angiodysplasia‑related GI bleeding and the implications of the OCEAN trial for VWD.
OCEAN trial:
- Multicenter RCT in 62 patients with transfusion‑dependent angiodysplasia‑related anemia, Octreotide LAR 40 mg q4w vs standard care.
- About 50% reduction in transfusion requirements (11.0 vs 21.2 units), alongside fewer endoscopic procedures and hospitalizations, with a generally favourable safety profile.
What octreotide actually does
Octreotide, a long‑acting somatostatin analogue, reduces splanchnic blood flow and portal pressure, improves platelet aggregation, and exerts anti‑angiogenic effects via inhibition of VEGF and other growth factors.
This mechanistic profile makes it particularly attractive for chronic bleeding from GI angiodysplasia.
What this could mean for VWD
Even though VWD patients were not included in OCEAN, these robust data provide the best evidence we currently have for systemic therapy in angiodysplasia‑related bleeding and strongly support octreotide as a potential first‑line systemic option in this setting.
Case reports and small series in VWD already suggest benefit, but dedicated prospective trials in VWD with angiodysplasia are urgently needed to define efficacy, safety, and optimal positioning in future treatment algorithms.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
May 6, 2026, 13:42Irogue Igbinosa: Rethinking Iron Deficiency in Pregnancy with Intravenous Therapy
-
May 6, 2026, 13:34Manaf Aljishi: Three Posters Presented at the Hematology and Hemostasis Conference 2026
-
May 6, 2026, 13:33David Ferreira: Insights from the 1st National Meeting of Young Immunohematologists in Abrantes
-
May 6, 2026, 13:22Nicholas Lee: Honored to Join ASH CRTI Program for Aplastic Anemia Research
-
May 6, 2026, 13:16Mehari Gebreyohanns: Transition from Alteplase to Tenecteplase Is Full Steam Ahead in Texas
-
May 6, 2026, 12:53Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
-
May 6, 2026, 12:36Alan Nurden: CRISPR-Mediated Megakaryocyte Modeling in Glanzmann Thrombasthenia
-
May 6, 2026, 12:12Mona Ranade: Insights from a Medeloop Analytics Study Evaluate Catheter-Directed Therapy in Pulmonary Embolism
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality